These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 26488196)

  • 1. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
    Qin L; Luo X; Zou KH; Snedecor SJ
    J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
    Angulo JC; Sánchez-Ballester F; Peral C; Rejas J; Ramos J; Snedecor SJ; Sudharshan L; Liu S; Luo X
    Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.
    Angulo JC; Valpas A; Rejas J; Linden K; Kvasz M; Snedecor SJ
    Clin Drug Investig; 2014 May; 34(5):297-307. PubMed ID: 24567280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
    Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
    Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
    Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacoeconomic study of using solifenacin for the treatment of urge urinary incontinence in patients with overactive bladder syndrome].
    Avksent'eva MV; Gerasimova KV; Khachatrian GR; Frolov MIu; Omel'ianovskiĭ VV; Avksent'ev NA
    Urologiia; 2014; (5):56-8, 60-1. PubMed ID: 25807761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
    Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
    Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of urgency urinary incontinence in the United States: a systematic review.
    Coyne KS; Wein A; Nicholson S; Kvasz M; Chen CI; Milsom I
    J Manag Care Pharm; 2014 Feb; 20(2):130-40. PubMed ID: 24456314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.
    Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
    BMC Urol; 2013 Oct; 13():51. PubMed ID: 24144225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
    Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
    BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.
    Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
    Clin Drug Investig; 2015 Dec; 35(12):795-805. PubMed ID: 26464261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine for the treatment of urge urinary incontinence.
    Elterman DS; Chughtai B; Kaplan SA; Barkin J
    Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.